{"id":223668,"date":"2025-10-19T23:03:19","date_gmt":"2025-10-20T04:03:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/10\/prognostic-impact-of-elevation-of-cancer-antigen-15-3-ca15-3-in-patients-with-early-breast-cancer-with-normal-serum-ca15-3-level"},"modified":"2025-10-19T23:03:19","modified_gmt":"2025-10-20T04:03:19","slug":"prognostic-impact-of-elevation-of-cancer-antigen-15-3-ca15-3-in-patients-with-early-breast-cancer-with-normal-serum-ca15-3-level","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/10\/prognostic-impact-of-elevation-of-cancer-antigen-15-3-ca15-3-in-patients-with-early-breast-cancer-with-normal-serum-ca15-3-level","title":{"rendered":"Prognostic Impact of Elevation of Cancer Antigen 15\u20133 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/prognostic-impact-of-elevation-of-cancer-antigen-15-3-ca15-3-in-patients-with-early-breast-cancer-with-normal-serum-ca15-3-level.jpg\"><\/a><\/p>\n<p>Breast cancer (BC) is the most common cancer in the world as well as the most common malignancy in Korean women, and the incidence continues to increase [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B1\" aria-describedby=\"B1\">1<\/a>, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B2\" aria-describedby=\"B2\">2<\/a>]. Due to increased early detection with cancer screening programs and advances in systemic treatment such as chemotherapy, anti-hormone therapy, and human epidermal growth factor 2 (HER2)-targeted therapy, more patients are surviving after treatment for BC [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B3\" aria-describedby=\"B3\">3<\/a>].<\/p>\n<p>Current surveillance guidelines for follow-up after a diagnosis of BC recommend regular mammography (MMG) and physical examinations as well as further symptom-related laboratory tests and imaging tests, such as computed tomography (CT) or positron emission tomography-CT scans [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B4\" aria-describedby=\"B4\">4<\/a>, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B5\" aria-describedby=\"B5\">5<\/a>]. These guidelines are based on data from clinical trials performed in the early 1990\u2019s, which did not show any survival benefit with the early detection of distant metastasis [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B6\" aria-describedby=\"B6\">6<\/a>, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B7\" aria-describedby=\"B7\">7<\/a>]. However, those clinical trials were mainly conducted using imaging modalities with poor sensitivity (e.g., chest X-ray), physical examinations with examiner-dependent variation of sensitivity (e.g., abdominal sonography), or procedures with limited specificity (e.g., bone scan), and did not include tumor markers (e.g., cancer antigen 15\u20133 [CA15-3]).<\/p>\n<p>CA15-3 is a serum tumor marker for BC extensively used in clinical practice. CA15-3 is non-invasive, easily available, and a cost-effective tumor marker for immediate diagnosis, monitoring, and prediction of BC in early, advanced, and metastatic BC [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B8\" aria-describedby=\"B8\">8<\/a>, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B9\" aria-describedby=\"B9\">9<\/a>, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10139845\/#B10\" aria-describedby=\"B10\">10<\/a>]. However, to the best of our knowledge, its clinical value within normal range has not been assessed. We hypothesized that an elevation of CA15-3 levels which were initially within normal ranges in patients with early BC could affect recurrence of BC; thus, the association between elevated CA15-3 levels and BC recurrence was analyzed in the present study.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Breast cancer (BC) is the most common cancer in the world as well as the most common malignancy in Korean women, and the incidence continues to increase [1, 2]. Due to increased early detection with cancer screening programs and advances in systemic treatment such as chemotherapy, anti-hormone therapy, and human epidermal growth factor 2 (HER2)-targeted [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-223668","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/223668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=223668"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/223668\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=223668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=223668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=223668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}